Background: Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.
Objective: To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve outcomes.
Methods: Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated in a series of interviews and group discussions designed to elicit tips for successful implementation.
Results: Clinicians identified 8 tips that were considered the most relevant, practical, and impactful for prescribers of Peanut (Arachis hypogaea) Allergen Powder-dnfp: (1) preparing to provide treatment, (2) assessing the medical indication for treatment and (3) shared decision making, (4) staff education, (5) establishing office processes, (6) managing patient expectations and using anticipatory guidance, (7) optimising adherence and (8) maintaining flexibility throughout the treatment process. In addition, a range of supporting materials (e.g., checklists and action plans) are provided.
Conclusion: The introduction of a novel therapy often requires healthcare providers to modify or adopt practices to effectively employ the treatment. The provision of guidance based upon early real-world experiences of licenced peanut OIT may help inform clinical practice and improve treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088027 | PMC |
| http://dx.doi.org/10.1186/s13223-022-00671-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.
J Allergy Clin Immunol
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address:
Background: Peanut allergy (PA) is one of the most prevalent food allergies with a lack of favorable safety/efficacy treatment. A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut) has been developed as a novel therapeutic approach for PA.
Objective: We assessed the tolerogenic properties and reactivity of VLP Peanut.
Keeping toxigenic section and aflatoxin contamination at bay by deploying atoxigenic-based biocontrol products during production of groundnut and maize in Mozambique.
Front Microbiol
November 2024
Pathology and Mycotoxin Unit, IITA, Ibadan, Nigeria.
Article Synopsis
- * A research study involved 468 groundnut and 558 maize farmers testing biocontrol products that use harmless fungi strains to combat aflatoxins, showing impressive results over two years.
- * Treated crops showed aflatoxin levels well within safe limits set by the EU and US, with reductions of 78-98% in groundnuts and 61-93% in maize, indicating the products' effectiveness in improving crop safety and quality.
Food allergy oral immunotherapy.
J Food Allergy
September 2020
From the Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Research Institute, Little Rock, Arkansas.
Food allergy oral immunotherapy (OIT) has demonstrated efficacy in promoting clinically relevant immunomodulation that leads to desensitization (reduced reactivity while on OIT) in the majority of treated individuals; however, sustained unresponsiveness after OIT cessation for a specified interval has only been observed in a subset. The potential therapeutic benefits of OIT must be balanced with the risk for adverse events. These adverse events may range from self-limited or easily treated oropharyngeal, respiratory, or gastrointestinal symptoms to persistent abdominal symptoms that lead to cessation of therapy and to anaphylaxis.
View Article and Find Full Text PDFWorld Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update - XII - Recommendations on milk formula supplements with and without probiotics for infants and toddlers with CMA.
World Allergy Organ J
April 2024
Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
Background: Cow's milk allergy (CMA) is the most common food allergy in infants. The replacement with specialized formulas is an established clinical approach to ensure adequate growth and minimize the risk of severe allergic reactions when breastfeeding is not possible. Still, given the availability of multiple options, such as extensively hydrolyzed cow's milk protein formula (eHF-CM), amino acid formula (AAF), hydrolyzed rice formula (HRF) and soy formulas (SF), there is some uncertainty as to the most suitable choice with respect to health outcomes.
View Article and Find Full Text PDFBronchoscopy-guided Cryotherapy for Airway Obstruction from Bronchial Cast.
J Community Hosp Intern Med Perspect
January 2024
Mayo Clinic Florida, USA.
The application of cryotherapy in the extraction of airway blood clots has gained increased precedence over Fogarty catheter and biopsy forceps. The cryoprobe, passed through a flexible bronchoscope, adheres and aids in the removal of foreign body through cryoadhesion within minutes. Besides blood clots, this method was found to be extremely efficient in removing different kinds of foreign bodies including food particles like peanuts, pills, and inspissated mucus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!